Two Faces of TGF-beta1 in Breast Cancer

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 2014 Jun 4

PMID 24891760

Citations 102

Authors

Joanna Magdalena Zarzynska

Affiliations

Soon will be listed here.

Abstract

Breast cancer (BC) is potentially life-threatening malignancy that still causes high mortality among women. Scientific research in this field is focused on deeper understanding of pathogenesis and progressing of BC, in order to develop relevant diagnosis and improve therapeutic treatment. Multifunctional cytokine TGF- β 1 is one of many factors that have a direct influence on BC pathophysiology. Expression of TGF- β 1, induction of canonical and noncanonical signaling pathways, and mutations in genes encoding TGF- β 1 and its receptors are correlated with oncogenic activity of this cytokine. In early stages of BC this cytokine inhibits epithelial cell cycle progression and promotes apoptosis, showing tumor suppressive effects. However, in late stages, TGF- β 1 is linked with increased tumor progression, higher cell motility, cancer invasiveness, and metastasis. It is also involved in cancer microenvironment modification and promotion of epithelial to mesenchymal transition (EMT). This review summarizes the current knowledge on the phenomenon called "TGF- β 1 paradox", showing that better understanding of TGF- β 1 functions can be a step towards development of new therapeutic approaches. According to current knowledge several drugs against TGF- β 1 have been developed and are either in nonclinical or in early stages of clinical investigation.

Citing Articles

Adenylate cyclase 9 expression level is associated with hormone receptor-positive breast cancer and predicts patient prognosis.

Sugino K, Shibata M, Adachi Y, Soeda I, Ichikawa T, Inaishi T Nagoya J Med Sci. 2025; 86(4):665-682.

PMID: 39780930 PMC: 11704764. DOI: 10.18999/nagjms.86.4.665.

Partial Inhibition of Epithelial-to-Mesenchymal Transition (EMT) Phenotypes by Placenta-Derived DBMSCs in Human Breast Cancer Cell Lines, In Vitro.

Basmaeil Y, Subayyil A, Kulayb H, Kondkar A, Alrodayyan M, Khatlani T Cells. 2025; 13(24.

PMID: 39768220 PMC: 11674051. DOI: 10.3390/cells13242131.

Transcriptional responses to direct and indirect TGFB1 stimulation in cancerous and noncancerous mammary epithelial cells.

Janus P, Kus P, Jaksik R, Vydra N, Toma-Jonik A, Gramatyka M Cell Commun Signal. 2024; 22(1):522.

PMID: 39468555 PMC: 11514872. DOI: 10.1186/s12964-024-01821-5.

ZNF8 Orchestrates with Smad3 to Promote Lung Metastasis by Recruiting SMYD3 in Breast Cancer.

Geng W, An J, Dong K, Zhang H, Zhang X, Liu Y Adv Sci (Weinh). 2024; 11(40):e2404904.

PMID: 39225541 PMC: 11515916. DOI: 10.1002/advs.202404904.

Epigenetic identification of LTBP4 as a putative tumor suppressor in breast cancer.

He W, Zhang J, Wen S, Li Y, Shen L, Zhou T Epigenomics. 2024; 16(14):999-1012.

PMID: 39193795 PMC: 11404579. DOI: 10.1080/17501911.2024.2388017.

References

Bueno L, De Alwis D, Pitou C, Yingling J, Lahn M, Glatt S . Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. Eur J Cancer. 2007; 44(1):142-50. DOI: 10.1016/j.ejca.2007.10.008. View

Micalizzi D, Wang C, Farabaugh S, Schiemann W, Ford H . Homeoprotein Six1 increases TGF-beta type I receptor and converts TGF-beta signaling from suppressive to supportive for tumor growth. Cancer Res. 2010; 70(24):10371-80. PMC: 3072046. DOI: 10.1158/0008-5472.CAN-10-1354. View

Seton-Rogers S, Lu Y, Hines L, Koundinya M, LaBaer J, Muthuswamy S . Cooperation of the ErbB2 receptor and transforming growth factor beta in induction of migration and invasion in mammary epithelial cells. Proc Natl Acad Sci U S A. 2004; 101(5):1257-62. PMC: 337040. DOI: 10.1073/pnas.0308090100. View

McGowan P, Duffy M . Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database. Ann Oncol. 2008; 19(9):1566-72. DOI: 10.1093/annonc/mdn180. View

Martinet W, Agostinis P, Vanhoecke B, Dewaele M, De Meyer G . Autophagy in disease: a double-edged sword with therapeutic potential. Clin Sci (Lond). 2009; 116(9):697-712. DOI: 10.1042/CS20080508. View

Ma L, Teruya-Feldstein J, Weinberg R . Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007; 449(7163):682-8. DOI: 10.1038/nature06174. View

Parvani J, Taylor M, Schiemann W . Noncanonical TGF-β signaling during mammary tumorigenesis. J Mammary Gland Biol Neoplasia. 2011; 16(2):127-46. PMC: 3723114. DOI: 10.1007/s10911-011-9207-3. View

Yilmaz M, Christofori G . EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009; 28(1-2):15-33. DOI: 10.1007/s10555-008-9169-0. View

Taylor M, Sossey-Alaoui K, Thompson C, Danielpour D, Schiemann W . TGF-β upregulates miR-181a expression to promote breast cancer metastasis. J Clin Invest. 2012; 123(1):150-63. PMC: 3533297. DOI: 10.1172/JCI64946. View

10.

Lee J, Lee K, Kim D, Heo D . Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol. 2004; 172(12):7335-40. DOI: 10.4049/jimmunol.172.12.7335. View

11.

Shah F, Shukla S, Shah P, Shukla H, Patel P . Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer. Indian J Cancer. 2009; 46(3):194-202. DOI: 10.4103/0019-509X.52953. View

12.

Vincent T, Neve E, Johnson J, Kukalev A, Rojo F, Albanell J . A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition. Nat Cell Biol. 2009; 11(8):943-50. PMC: 3769970. DOI: 10.1038/ncb1905. View

13.

Cheng N, Bhowmick N, Chytil A, Gorksa A, Brown K, Muraoka R . Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene. 2005; 24(32):5053-68. PMC: 3074577. DOI: 10.1038/sj.onc.1208685. View

14.

Hinshelwood R, Huschtscha L, Melki J, Stirzaker C, Abdipranoto A, Vissel B . Concordant epigenetic silencing of transforming growth factor-beta signaling pathway genes occurs early in breast carcinogenesis. Cancer Res. 2007; 67(24):11517-27. DOI: 10.1158/0008-5472.CAN-07-1284. View

15.

Lamouille S, Connolly E, Smyth J, Akhurst R, Derynck R . TGF-β-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion. J Cell Sci. 2012; 125(Pt 5):1259-73. PMC: 3324583. DOI: 10.1242/jcs.095299. View

16.

Imamura T, Hikita A, Inoue Y . The roles of TGF-β signaling in carcinogenesis and breast cancer metastasis. Breast Cancer. 2011; 19(2):118-24. DOI: 10.1007/s12282-011-0321-2. View

17.

Zhao B, Hoffmann F . Inhibition of transforming growth factor-beta1-induced signaling and epithelial-to-mesenchymal transition by the Smad-binding peptide aptamer Trx-SARA. Mol Biol Cell. 2006; 17(9):3819-31. PMC: 1556379. DOI: 10.1091/mbc.e05-10-0990. View

18.

Meulmeester E, Ten Dijke P . The dynamic roles of TGF-β in cancer. J Pathol. 2010; 223(2):205-18. DOI: 10.1002/path.2785. View

19.

Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A . Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest. 2003; 112(12):1809-20. PMC: 297002. DOI: 10.1172/JCI20039. View

20.

Wendt M, Allington T, Schiemann W . Mechanisms of the epithelial-mesenchymal transition by TGF-beta. Future Oncol. 2009; 5(8):1145-68. PMC: 2858056. DOI: 10.2217/fon.09.90. View